AIM AIM ImmunoTech Inc.
Price Chart
Executive Summary
AIM ImmunoTech announced positive Phase 2 data for Ampligen in recurrent ovarian cancer, showing a 50% objective response rate, 32.5-month median overall survival, and no Grade 4/5 toxicities. The results suggest Ampligen may overcome immunotherapy resistance, but larger trials are needed.
Actionable Insight
The strong efficacy and safety data could attract partnership interest or funding for later-stage trials. Monitor for secondary endpoint completion in January 2027 and any subsequent partnership announcements.
Key Facts
- 50% Objective Response Rate (ORR) including 21% complete responses
- 79% Clinical Benefit Rate
- Median Overall Survival of 32.5 months
- Durable responses exceeding 70+ months in select patients
- No Grade 4 or 5 toxicities observed
- Single-arm Phase 2 trial; final secondary endpoint data expected January 2027
Financial Impact
Pre-revenue company; data supports future partnership/licensing potential but no immediate financial impact
Risk Factors
- Single-arm Phase 2 trial design limits comparative efficacy conclusions
- Requires larger randomized trials for regulatory approval
- Small market cap ($4M) and cash burn risk; may need dilution to fund development
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3289988 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 20, 2026
today
|
Press Release
| $0.4349 awaiting T+5 | awaiting T+5 | — | $0.2499 (+42.54%) |
|
May 19, 2026
1d ago
|
424B5
| $0.3850 awaiting T+5 | awaiting T+5 | — | $0.2499 (−35.09%) |
|
May 19, 2026
2d ago
|
8-K
| $0.3570 awaiting T+5 | awaiting T+5 | — | $0.2499 (−30.00%) |
|
May 14, 2026
7d ago
|
8-K
| $0.2703 awaiting T+5 | awaiting T+5 | — | $0.2499 (−7.55%) |
|
May 14, 2026
7d ago
|
Press Release
| $0.2703 awaiting T+5 | awaiting T+5 | — | $0.2499 (−7.55%) |
|
May 12, 2026
8d ago
|
8-K
| $0.2700 $0.4100 | ▼ −51.85% | ▼ −53.01% | $0.2499 (+7.44%) |
|
May 7, 2026
14d ago
|
Press Release
| $0.5600 $0.2700 | ▼ −51.79% | ▼ −53.29% | $0.2499 (−55.38%) |
|
Apr 13, 2026
5w ago
|
Press Release
| $0.5800 $0.4900 | ▲ +15.52% | ▲ +16.91% | $0.2499 (+56.91%) |
|
Apr 10, 2026
5w ago
|
8-K
| $0.5300 $0.4900 | ▲ +7.55% | ▲ +10.84% | $0.2499 (+52.85%) |
|
Apr 10, 2026
5w ago
|
424B5
| $0.5300 $0.4900 | ▲ +7.55% | ▲ +10.84% | $0.2499 (+52.85%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access